PharVision Advisers’s Dynex Capital DX Stock Holding History

PharVision Advisers’s Portfolio DX Stock Details DX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,400	Closed	-$128K	–	767
2025 Q3	$128K	Buy	+10,400	New	+$130K	0.07%	592

Other funds holding DX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

PharVision Advisers's DX Position: Q4 2025 in Review

PharVision Advisers sold out of Dynex Capital (DX) in Q4 2025, closing a stake of 10,400 shares — an estimated $128K sold.

PharVision Advisers first reported a position in DX in Q3 2025 and held it in 1 quarter. The position peaked at $128K in Q3 2025. 262 funds tracked by Wall St. Rank hold DX as of Q4 2025.

PharVision Advisers reported no remaining Dynex Capital position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 10,400 Dynex Capital shares in Q4 2025, an estimated $128K.
PharVision Advisers first reported a position in Dynex Capital in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Dynex Capital position peaked at $128K in Q3 2025.
262 funds tracked by Wall St. Rank held Dynex Capital as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.